S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

PTN Palatin Technologies Inc New

1.97

0.07 (3.68%)

Last Updated: 10:02:27

Delayed by 15 minutes

Form 424B3 - Prospectus [Rule 424(b)(3)]

null

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Palatin Technologies Charts.

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Palatin Technologies Charts.

Palatin Technologies Inc New News

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Friday 21 June 2024 (1 week ago) • PR Newswire (US)

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
Thursday 20 June 2024 (1 week ago) • PR Newswire (US)

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Wednesday 12 June 2024 (2 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Wednesday 15 May 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 15 May 2024 (1 month ago) • Edgar (US Regulatory)

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Wednesday 15 May 2024 (1 month ago) • PR Newswire (US)

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
Thursday 9 May 2024 (2 months ago) • PR Newswire (US)

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Thursday 2 May 2024 (2 months ago) • PR Newswire (US)

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Tuesday 30 April 2024 (2 months ago) • PR Newswire (US)

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Monday 8 April 2024 (3 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (4 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Monday 4 March 2024 (4 months ago) • Edgar (US Regulatory)

More Palatin Technologies Inc New News Articles

Ethema Health (PK)

New Momentum (PK)

Ecare Solutions (PK)

Decentral Life (PK)

SMC Entertainment (PK)

Brookmount Explorations (PK)

FuelCell Energy

1812 Brewing (PK)

TPT Global Tech (PK)

Faraday Future Intellige...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions